

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



奧園健康生活集團有限公司

AOYUAN HEALTHY LIFE GROUP COMPANY LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3662)

INSIDE INFORMATION

This announcement is made by Aoyuan Healthy Life Group Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 21 March 2022 in relation to a meeting of the board (the “**Board**”) of directors of the Company (the “**Board Meeting**”) to be held on 31 March 2022 for the purpose of, among other matters, considering and approving the annual results of the Group for the financial year ended 31 December 2021 (the “**2021 Annual Results**”).

DELAY IN PUBLICATION OF 2021 ANNUAL RESULTS AND DESPATCH OF 2021 ANNUAL REPORT

Based on the information currently available to the Company, additional time and procedures were required by the auditor of the Company to conduct the audit of the 2021 Annual Results, resulting in the publication of the 2021 Annual Results later than the expected timetable. The delay in the publication of the 2021 Annual Results on or before 31 March 2022 was mainly attributable to reasons including (a) the implementation of preventive and control measures, including travel restrictions and quarantine measures, in connection with the recent recurrence of the COVID-19 pandemic, having disrupted the progress of sorting and collecting financial data for the 2021 Annual Results; and (b) the request from the auditor of the Company during the course of the audit of the 2021 Annual Results as set out in its letter to the audit committee of the Company dated 25 March 2022 for additional information on the fund flows with the related parties of the Group. Upon receipt of the said letter from the Company’s auditor, the audit committee of the Company has taken immediate actions accordingly, including but not

limited to exploring suitable independent advisors to assist the audit committee in carrying out independent investigations on the said fund flows with independent legal advice. The Board understands that such process will inevitably cause further delay in the completion of the audit work for the 2021 Annual Results. As such, the 2021 Annual Results will not be ready for publication by 31 March 2022 in compliance with Rule 13.49(1) of the Listing Rules.

Based on the above, after due and careful consideration, the Board is of the view that it would not be appropriate for the Company to publish the unaudited consolidated management accounts of the Group for the year ended 31 December 2021 (the “**2021 Unaudited Management Accounts**”) at this stage pursuant to Rule 13.49(3) of the Listing Rules as they might not accurately reflect the financial performance and position of the Group and the publication of the 2021 Unaudited Management Accounts might cause confusion and be misleading to the shareholders and potential investors of the Company.

As a result of the delay in the publication of the 2021 Annual Results, there will also be a delay in the despatch of the Company’s annual report for the financial year ended 31 December 2021 (the “**2021 Annual Report**”) in accordance with Rule 13.46(2)(a) of the Listing Rules.

POSTPONEMENT OF MEETING OF THE BOARD AND SUSPENSION OF TRADING

Due to the aforementioned delay in the publication of the 2021 Annual Results, the Board Meeting originally scheduled on 31 March 2022 to, among others, consider and approve the 2021 Annual Results will be postponed. The Company will continue to work with its auditor closely to publish the 2021 Annual Results and despatch the 2021 Annual Report as soon as practicable.

Accordingly, the Company will apply for suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on Friday, 1 April 2022 as required under Rule 13.50 of the Listing Rules, pending the publication of the 2021 Annual Results.

The Company will publish further announcement(s) to inform the shareholders and potential investors of the Company of (a) the date of the Board Meeting to approve the 2021 Annual Results; (b) the latest development in the completion of the audit processes; (c) the date of despatch of the 2021 Annual Report; and (d) trading in the shares of the Company in accordance with the Listing Rules and applicable laws as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Aoyuan Healthy Life Group Company Limited
Guo Zining
Chairman

Hong Kong, 30 March 2022

As at the date of this announcement, the executive directors of the Company are Mr. Zheng Wei and Mr. Cheng Siu Fai; the non-executive directors of the Company are Mr. Guo Zining and Mr. Ruan Yongxi; and the independent non-executive directors of the Company are Mr. Hung Ka Hai Clement, Dr. Li Zijun and Mr. Wang Shao.